October 11, 2022•Publication
Gate MRI’s Head of Vaccine Development, Alex Schmidt, joins a panel of international experts on a recent consensus statement for the development of TB vaccines in those with HIV. The paper outlines recommendations for vaccine developers on which vaccines, patient populations, and efficacy endpoints to prioritize when investigating a TB vaccine in individuals with HIV as well as ethical and regulatory factors to consider.
As chief medical officer and head of development at the Bill & Melinda Gates Medical Research Institute, Michael W. Dunne, M.D., oversees clinical trials in therapeutic areas aligned with the mission of the Gates Foundation. Over the course of his career, Michael has played an integral role in global and…
Our mantras represent how we want to get to impact, and the behaviors we will collectively encourage as part of our corporate culture. These concepts are broad; they may be understood and demonstrated differently by our diverse workforce. It is important we achieve a shared understanding of what…
February 14, 2024•Publication
August 17, 2022•Press Release
The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the execution of a joint development agreement (JDA) — among Janssen Pharmaceutica NV, Otsuka, TB Alliance and the Bill & Melinda Gates Medical Research Institute — supporting the progression of two investigational tuberculosis (TB) combination treatment regimens into phase 2 clinical development.
